万孚生物上市九项新品

Core Insights - Guangzhou Wondfo Biotech Co., Ltd. has received approval from the National Medical Products Administration and the Guangdong Provincial Medical Products Administration for nine self-developed test kits [1] - The newly approved thrombus five-item test and tumor marker test kits will provide a richer testing menu and more convenient combinations for clinical use [1] Group 1: Product Development - The thrombus five-item test, including D-Dimer, aids in the auxiliary diagnosis of thrombotic diseases, early diagnosis of DIC, monitoring of thrombolytic and anticoagulant drug efficacy, and diagnosis of vascular endothelial system damage [1] - Wondfo Biotech has launched multiple fully automated chemiluminescence immunoassay analyzers with varying throughput, catering to different application scenarios [1] Group 2: Market Position and Future Plans - The company has obtained over 150 medical device product registrations globally, covering nine major areas including cardiac markers, inflammation, thrombosis, thyroid, sex hormones, anemia, bone metabolism, tumors, and infectious disease testing [1] - Wondfo Biotech aims to continue leveraging its high-level, global R&D innovation system, focusing on technological, product, and service innovations to benefit the public [1]